Evaluation of pelvic muscle strength in women during treatment for cervical cancer

Oncological treatment and the functionality of the pelvic floor muscles (PFM) in women with Cervical Cancer: prospective cohort

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

REBEC

Registry ID

RBR-10jjsm26

Enrollment

Registered

2026-04-28

Start date

2023-02-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stricture and atresia of vagina

Interventions

Prospective cohort study involving 85 women diagnosed with cervical cancer. Follow-up consists of functional assessments at three distinct moments: baseline (pre-oncological treatment), followed by re

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Women with a confirmed diagnosis of cervical cancer; patients with an indication for oncological treatment (surgery, radiotherapy, chemotherapy, or brachytherapy); age 18 years or older; ability to understand and sign the Informed Consent Form (ICF)

Exclusion criteria

Exclusion criteria: Patients with metastatic tumors with exclusive indication for palliative treatment; women unable to undergo functional clinical examination (digital palpation); presence of cognitive conditions that prevent the understanding of questionnaires; refusal to participate in any stage of data collection

Design outcomes

Primary

Measure	Time frame
To evaluate pelvic floor muscle function, verified by digital palpation, by observing a reduction in strength and endurance levels comparing baseline with post-treatment moments (3 and 6 months) (Oxford Modified Scale);To evaluate female sexual function, verified by the (FSFI - Female Sexual Function Index) questionnaire, by observing variations in total and specific domain scores during follow-up assessments	—

Measure

Time frame

To evaluate pelvic floor muscle function, verified by digital palpation, by observing a reduction in strength and endurance levels comparing baseline with post-treatment moments (3 and 6 months) (Oxford Modified Scale);To evaluate female sexual function, verified by the (FSFI - Female Sexual Function Index) questionnaire, by observing variations in total and specific domain scores during follow-up assessments

—

Secondary

Measure	Time frame
To evaluate the presence and grade of vaginal stenosis, verified by the LENT-SOMA scale, based on the observation of changes in vaginal depth and diameter graded from 1 to 4 according to the severity of sequelae observed at 3 and 6 months post-treatment	—

Countries

Contacts

Public ContactTaynara Pilger

Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo FMRP/USP

taynara.pilger@usp.br+5516996516798

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Jun 11, 2026